Trial of Radiotherapy for Lung Metastases in Soft Tissue Sarcoma

Share this content:
Researchers are evaluating stereotactic body radiation therapy with adaptive radiation therapy for the treatment of non-resectable lung metastases from a primary soft tissue sarcoma.
Researchers are evaluating stereotactic body radiation therapy with adaptive radiation therapy for the treatment of non-resectable lung metastases from a primary soft tissue sarcoma.

Title: Pilot Study Evaluating Stereotactic Body Radiation Therapy (SBRT) and Adaptive Radiation Therapy (ART) for Pulmonary Metastases From Soft Tissue Sarcomas1

Principal Investigators: Manpreet Bedi, MD, Medical College of Wisconsin

Description: For this non-randomized, single arm study, researchers are evaluating stereotactic body radiation therapy (SBRT) with adaptive radiation therapy (ART) for the treatment of non-resectable lung metastases from a primary soft tissue sarcoma.

Patients must be 18 years or older with 1 to 5 lung metastases; no metastasis can be larger than 5 cm.

SBRT with ART will be used for all patients; each metastasis will receive 3 to 5 fractions; 1 to 3 treatments will be conducted per week until completion. Follow-up will occur for 3 years.

The primary outcome is safety and toxicity; secondary outcomes include local/regional control, quality of life, and overall survival.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01949506.

Status: This study is open and recruiting participants as of April 17, 2017.

This study is sponsored by the Medical College of Wisconsin.

Reference

  1. Clinicaltrials.gov. (SBRT) and (ART) for pulmonary metastases from soft tissue sarcomas. NCT01949506. https://clinicaltrials.gov/ct2/show/NCT01949506. Accessed April 17, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters